I am a
Home I AM A Search Login

Papers of the Week


2022 Jul 08


Hepatol Res

Sofosbuvir-Velpatasvir in Adults With Hepatitis C Virus Infection and Compensated Cirrhosis in Japan.

Authors

Takehara T, Izumi N, Mochida S, Genda T, Fujiyama S, Notsumata K, Tamori A, Suzuki F, Suri V, Mercier R-C, Matsuda T, Matsuda K, Kato N, Chayama K, Kumada H
Hepatol Res. 2022 Jul 08.
PMID: 35802063.

Abstract

Protease-free regimens for chronic hepatitis C virus (HCV) infection are safe and effective for persons with either compensated or decompensated cirrhosis. We examined the efficacy and safety of sofosbuvir-velpatasvir in participants with HCV and compensated cirrhosis in Japan.